This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Efficacy of Olanzapine: An Overview of Pivotal Clinical Trials

Charles M. Beasley, Jr., M.D., Gary D. Tollefson, M.D., Ph.D., and Pierre V. Tran, M.D.

Published: February 1, 1997

Article Abstract

Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepineclass. Its relatively greater binding affinity for 5-HT2 compared to D2 receptors makes it similarto the atypical agent clozapine, a serotonin/dopamine antagonist. Four double-blind pivotal studies,which compare olanzapine to placebo and/or haloperidol, are presented. The results suggest thatolanzapine is as effective as haloperidol for positive symptoms and more effective than haloperidolfor the treatment of the negative symptoms of schizophrenia.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: